Personalized medicine—developing individualized drug therapies for patients—will be an increasingly important part of health care. But the foundation of personalized medicine, diagnostics methods, are under increasing attack from the courts and the Patent and Trademark Office. These court decisions and U.S. Patent Office actions are likely to have a significant impact on the personalized medicine industry.
Dr. Bob Wassman, previously national medical director of Genzyme genetics, and David Resnick and Ronald Eisenstein, Nixon Peabody LLP, will discuss the current and future state of the personalized medicine industry, and recent case law and patent office developments.
To register for this event or for more information, please contact Allison Weimer at 617-345-1297 or email@example.com.